Category Archives: Emerging Markets
European Pharma 1981-2011: Survival of the Fittest?
This month sees Pharmaceutical Executive magazine reach its 30th birthday. In line with that milestone, Reflector assesses what the last three decades have meant for European pharma — and shows how the game has changed beyond recognition.
Thirty years is a long time in any industry. The coalmining industry, the market for air travel, or telecommunications [...]
Also posted in Europe, Global, Guest Blog, IP, Pharm Exec Magazine, R&D, Regulatory, healthcare, leadership Tagged EU, European Union, GlaxoSmithKline, Hoffman-La Roche, Merck Sharp Dohme, parallel trading, Sanofi Leave a comment
Planning Beyond the Petri Dish: A Pfizer Case Study
Pfizer’s crizotinib development program combined organization, art, and science— and a large dose of unforeseen risk.
The path to commercializing a breakthrough discovery is rarely a linear process. The orderly rationale of the scientific method is often overtaken by the random artistry of passion, personality, business culture, and sheer luck. Each plays a [...]
Also posted in Global, R&D Tagged Asia, crizotinib, Emerging Markets, Japan, Korea, NSCLC, Pfizer, R&D Leave a comment
Indian Government Proposes Ban on Physician Gifts
India’s Department of Pharmaceuticals released a 14-page “voluntary code” for drug marketers, which includes a strict ban on gifts to prescribers, among other things.
The code, which is open for public comment until June 30th, states that “no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to persons qualified to prescribe” [...]
Also posted in Advertising, Global, Marketing, Medical Education, Strategy Tagged Emerging Markets, Global, india, Marketing, Professional Marketing, promotions, Regulatory Leave a comment
Biosimilars Spend to Reach $2.5 Bln by 2015: IMS
Global spending on biosimilars is expected to reach between $2 and $2.5 billion by 2015, up from $311 million in 2010, according to an IMS forecast. Total spend on biologics is expected to climb as high as $200 billion.
On a call with reporters yesterday, Murray Aitken, executive director of the IMS Institute for Healthcare Informatics, [...]
Also posted in Agency Insight, Biotech, Europe, Strategy Tagged biosimilars, forecast, IMS Health 1 Comment

Tiered Pricing Not Always a Win-Win